Literature DB >> 33306628

Prognostic value of imaging markers from 18FDG-PET/CT in paediatric patients with Hodgkin lymphoma.

Mónica G Rodríguez Taroco1, Enrique G Cuña1,2, Carolina Pages3, Magdalena Schelotto3, Gabriel A González-Sprinberg2, Luis A Castillo3, Omar Alonso1,4.   

Abstract

OBJECTIVE: Identification of imaging prognostic parameters for early therapy personalisation to reduce treatment-related morbidity in paediatric Hodgkin lymphoma (HL). Our aim was to evaluate quantitative markers from baseline 2-[18F]fluoro-2-deoxy-d-glucose PET/CT as prognostic factors for treatment outcomes. Another goal was assessing the prognostic value of Deauville score at interim PET/CT.
METHODS: Twenty-one patients were prospectively enrolled. Median age was 12 years (range 6-17); 13 were female. Patients underwent PET/CT for disease staging (bPET), at the end of two cycles of chemotherapy (iPET) and after chemotherapy. A total of 173 lesions were segmented from bPET. We calculated 51 texture features for each lesion. Total metabolic tumour volume and total lesion glycolysis from bPET were calculated for response prediction at iPET. Univariate and multivariate analyses were used for optimal cut-off values to separate responders at iPET according to the Deauville score.
RESULTS: We identified four texture features as possible independent predictors of treatment outcomes at iPET. The areas under the ROC for univariate analysis were 0.89 (95% CI, 0.75-1), 0.82 (95% CI, 0.64-1), 0.79 (95% CI, 0.59-0.99) and 0.89 (95% CI, 0.75-1). The survival curves for patients assigned Deauville scores 1, 2, 3 and X were different from those assigned a score 4, with 4-year progression free-survival (PFS) rates of 85 versus 29%, respectively (P = 0.05).
CONCLUSIONS: We found four textural features as candidates for predicting early response to chemotherapy in paediatric patients with HL. The Deauville score at iPET was useful for differentiating PFS rates.
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Year:  2021        PMID: 33306628     DOI: 10.1097/MNM.0000000000001337

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  3 in total

Review 1.  Artificial Intelligence in Lymphoma PET Imaging:: A Scoping Review (Current Trends and Future Directions).

Authors:  Navid Hasani; Sriram S Paravastu; Faraz Farhadi; Fereshteh Yousefirizi; Michael A Morris; Arman Rahmim; Mark Roschewski; Ronald M Summers; Babak Saboury
Journal:  PET Clin       Date:  2022-01

2.  Prognostic significance of clinical characteristics and 18Fluorodeoxyglucose-positron emission tomography/computed tomography quantitative parameters in patients with primary mediastinal B-cell lymphoma.

Authors:  Yizhen Liu; Jinjin Jiang; Lianfang Liu; Zezhou Wang; Baohua Yu; Zuguang Xia; Qunling Zhang; Dongmei Ji; Xiaojian Liu; Fangfang Lv; Xiaonan Hong; Shaoli Song; Junning Cao
Journal:  J Int Med Res       Date:  2022-01       Impact factor: 1.671

Review 3.  Clinical Perspectives for 18F-FDG PET Imaging in Pediatric Oncology: Μetabolic Tumor Volume and Radiomics.

Authors:  Vassiliki Lyra; Sofia Chatziioannou; Maria Kallergi
Journal:  Metabolites       Date:  2022-02-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.